BGMD (BG Medicine) Ending Cash Position: $1.53 Mil (As of Dec. 2015)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is BG Medicine Ending Cash Position?

BG Medicine BGMD -99.00% Ending Cash Position is $1.53 Mil as of Dec. 2015.

BG Medicine's Ending Cash Position for the quarter that ended in Dec. 2015 was $1.53 Mil.

BG Medicine's quarterly Ending Cash Position increased from Jun. 2015 ($0.18 Mil) to Sep. 2015 ($2.64 Mil) but then declined from Sep. 2015 ($2.64 Mil) to Dec. 2015 ($1.53 Mil).

BG Medicine's annual Ending Cash Position declined from Dec. 2013 ($7.75 Mil) to Dec. 2014 ($4.12 Mil) and declined from Dec. 2014 ($4.12 Mil) to Dec. 2015 ($1.53 Mil).

BG Medicine Ending Cash Position Related Terms

BG Medicine Ending Cash Position Historical Data

* Premium members only.

The historical data trend for BG Medicine's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BG Medicine Ending Cash Position Chart

BG Medicine Annual Data
Trend Dec05 Dec06 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.87 12.79 7.75 4.12 1.53

BG Medicine Quarterly Data
Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.12 1.61 0.18 2.64 1.53

BG Medicine Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

BG Medicine's Ending Cash Position for the fiscal year that ended in Dec. 2015 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=4.123+-2.598
=1.53

BG Medicine's Ending Cash Position for the quarter that ended in Dec. 2015 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=2.642+-1.117
=1.53

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $1.53 Mil mean?
BG Medicine (BGMD) has a Ending Cash Position of $1.53 Mil as of Dec. 2015. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on BG Medicine and its competitors.
Is BG Medicine's Ending Cash Position too high?
BG Medicine's current Ending Cash Position is $1.53 Mil.
How does BG Medicine's Ending Cash Position compare to LENSF and WHSI?
BG Medicine's Ending Cash Position of $1.53 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Devices & Instruments company?
A good Ending Cash Position depends on the Medical Devices & Instruments industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on BG Medicine and its competitors. BG Medicine's current Ending Cash Position is $1.53 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BG Medicine stock overvalued right now?
BG Medicine (BGMD) has a current Ending Cash Position of $1.53 Mil. The current Ending Cash Position is $1.53 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For BG Medicine (BGMD), the current Ending Cash Position is $1.53 Mil as of Dec. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BG Medicine Business Description

Address 303 Wyman Street, Suite 300, Waltham, MA, USA, 02451
BG Medicine Inc manufacture and sell diagnostic products that are used to guide the patients suffering from heart failure and related disorders in the United States. It distributes its products such as BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme-linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke.